| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 广州安必平医药科技股份有限公司（股票代码：688393）成立于2005年，是国内病理诊断领域上市企业，聚焦肿瘤筛查与精准诊断的产品+服务，集研发、生产、市场、服务、教育五位一体，服务全国近3000家医疗机构，为国内病理产品齐全、种类丰富、业务多元的高新技术企业之一。 安必平制定病理科“四化”发展战略——“自动化、标准化、数字化、智能化”，已完成从生物原材料、病理科室产品、数智科技软件到病理能力提升服务的全产业链发展布局，自产自研了智慧液基细胞（LBC）、免疫组化（IHC）、荧光原位杂交（FISH）、数智病理(DIP)等技术平台的配套设备、试剂耗材，获得了“国家高新技术企业”、“国家专精特新小巨人企业”、“广东省病理诊断工程技术研究中心”等多项荣誉。 同时，安必平积极响应国家政策的号召，为解决病理行业人才匮乏、基层医院病理能力薄弱等发展难题，以“产品+服务”的双轮驱动模式，拓展了智慧病理科建设、病理科能力提升等业务，用实际行动推动病理行业高质量发展。 目前，安必平在广州、上海、苏州设立3大研发中心，16项产品获得CE欧盟、英国标准协会（BSI）和日本厚生劳动省质量认证，业务覆盖国内31个省市，逐步拓展海外市场，始终坚持用精准医学诊断造福社会，致力于成为中国病理诊断领域的领先企业。 | ||||||||||||||||||||||||
| Main Business | 病理诊断试剂和仪器的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 蔡向挺 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 侯全能 | ||||||||||||||||||||||||
| Solicitors | 广东信达律师事务所 | ||||||||||||||||||||||||
| Auditors | 中汇会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 020-32299997-8118;020-32210051 | ||||||||||||||||||||||||
| Fax No | 020-32290284 | ||||||||||||||||||||||||
| Website | www.gzlbp.com | ||||||||||||||||||||||||
| zqswb@gzlbp.com;dukun@gzlbp.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 20/08/2020 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.500 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.100 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 12.654 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.910B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |